Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.51 |
| ▸ | HTR1A | P08908 | 6/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29922358 | 1.00 | HTR2C (0.60) | HTR2CSLC18A3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL5839494 | 0.88 | HTR2C (0.47) | HTR2CSLC18A3SIGMAR1 | |
| SCHEMBL744815 | 0.84 | ALOX15 (0.45) | HTR2C | |
| SCHEMBL30493303 | 0.84 | HTR2C (0.72) | HTR2CSLC18A3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL27584180 | 0.81 | HTR2C (0.49) | HTR2CSLC18A3SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL1068978 | 0.80 | NOS1 (0.41) | HTR2C | |
| SCHEMBL1067058 | 0.80 | KDM4E (0.44) | HTR2C | |
| SCHEMBL8786474 | 0.78 | KDM4E (0.47) | HTR2C | |
| SCHEMBL570948 | 0.78 | KDM4E (0.47) | HTR2C | |
| SCHEMBL4849477 | 0.78 | KDM4E (0.47) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109678788-A | A kind of 1,2- diaryl indoles, derivative and its synthetic method | 湘潭大学 | 2019-04-26 | — | — | CN | claimed |
| CN-107205972-A | Substituted N- (2- (amino) -2-oxoethyl) benzamide inhibitors of autotaxin and their preparation and use in the treatment of LPA-dependent or LPA-mediated diseases | X-RX股份有限公司 | 2017-09-26 | — | — | CN | claimed |
| EP-4731223-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | Universitat De Barcelona (ES) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024261340-A1 | MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY | UNIVERSITAT DE BARCELONA (ES) | 2024-12-26 | — | — | WO | disclosed |
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-20200199282-A1 | Modified Block Copolymer, Method for Producing Modified Block Copolymer, and Resin Composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-06-25 | — | — | US | disclosed |
| EP-3623398-A1 | MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION | Asahi Kasei Kabushiki Kaisha (JP) | 2020-03-18 | — | — | EP | disclosed |
| WO-2019164846-A1 | N-(PHENYL)-2-(PHENYL)PYRIMIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HPK1 INHIBITORS FOR TREATING CANCER | INCYTE CORPORATION (US) | 2019-08-29 | — | — | WO | disclosed |
| CN-108299411-A | 4,4- diphenyl-piperidine classes compound or pharmaceutically acceptable salt thereof, pharmaceutical composition and purposes | 中国人民解放军军事医学科学院毒物药物研究所 | 2018-07-20 | — | — | CN | disclosed |
| EP-2699569-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-1433783-A2 | Naphthalenecarboxamides as tachykinin receptor antagonists | AstraZeneca AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| CN-1322196-A | Naphthalenecarboxamides as tachykinin receptor antagonists | ASTRA ZENECA N N (SE) | 2001-11-14 | — | — | CN | disclosed |
| CN-1309638-A | N-substituted naphthamides as neurokinin receptor antagonists | ASTRAZENECA AB (SE) | 2001-08-22 | — | — | CN | disclosed |
| EP-1119551-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000020389-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
| US-3995045-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-11-30 | — | — | US | disclosed |